188 related articles for article (PubMed ID: 35224054)
1. RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study.
Riccio E; Capuano I; Buonanno P; Andreucci M; Provenzano M; Amicone M; Rizzo M; Pisani A
Front Cardiovasc Med; 2022; 9():824095. PubMed ID: 35224054
[TBL] [Abstract][Full Text] [Related]
2. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
Jun M; Jardine MJ; Perkovic V; Pilard Q; Billot L; Rodgers A; Rogers K; Gallagher M
PLoS One; 2019; 14(3):e0213192. PubMed ID: 30845156
[TBL] [Abstract][Full Text] [Related]
3. Prescription patterns of sodium and calcium polystyrene sulfonate in patients with hyperkalemia and chronic kidney disease receiving RAAS inhibitors.
Ren H; Leon SJ; Whitlock R; Rigatto C; Komenda P; Bohm C; Collister D; Tangri N
Clin Kidney J; 2022 Sep; 15(9):1713-1719. PubMed ID: 36003673
[TBL] [Abstract][Full Text] [Related]
4. Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease.
Garlo KG; Bates DW; Seger DL; Fiskio JM; Charytan DM
JAMA Netw Open; 2018 Nov; 1(7):e183874. PubMed ID: 30646338
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes.
An J; Zhou H; Ni L; Harrision TN; Wei R; Agiro A; Brahmbhatt YG; Oluwatosin Y; Schilling CG; Sim JJ
Am J Nephrol; 2023; 54(7-8):258-267. PubMed ID: 37231821
[TBL] [Abstract][Full Text] [Related]
6. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
[TBL] [Abstract][Full Text] [Related]
7. Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: A population-based analysis.
Jiménez-Marrero S; Cainzos-Achirica M; Monterde D; Vela E; Enjuanes C; Yun S; Garay A; Moliner P; Corbella M; Jovells-Vaqué S; Alcoberro L; Pons-Riverola A; Ramos-Polo R; Morillas H; Gómez-Hospital JA; Comin-Colet J
Eur J Intern Med; 2024 Mar; ():. PubMed ID: 38548513
[TBL] [Abstract][Full Text] [Related]
8. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
Degli Esposti L; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Santoro A
G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580544
[TBL] [Abstract][Full Text] [Related]
9. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.
Leon SJ; Whitlock R; Rigatto C; Komenda P; Bohm C; Sucha E; Bota SE; Tuna M; Collister D; Sood M; Tangri N
Am J Kidney Dis; 2022 Aug; 80(2):164-173.e1. PubMed ID: 35085685
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of RAAS Inhibition in Children with Advanced CKD.
van den Belt SM; Heerspink HJL; Kirchner M; Gracchi V; Thurn-Valsassina D; Bayazit AK; Niemirska A; Canpolat N; Kaplan Bulut I; Azukaitis K; Duzova A; Bacchetta J; Shroff R; Paripovic D; Özçakar ZB; Fidan K; Erdogan H; Gellermann J; Wühl E; de Zeeuw D; Melk A; Querfeld U; Schaefer F
Clin J Am Soc Nephrol; 2020 May; 15(5):625-632. PubMed ID: 32253275
[TBL] [Abstract][Full Text] [Related]
11. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study.
Agiro A; An A; Cook EE; Mu F; Chen J; Desai P; Oluwatosin Y; Pollack CV
Adv Ther; 2023 Jun; 40(6):2886-2901. PubMed ID: 37140706
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia.
Kanda E; Rastogi A; Murohara T; Lesén E; Agiro A; Arnold M; Chen G; Yajima T; Järbrink K; Pollack CV
BMC Nephrol; 2023 Jan; 24(1):18. PubMed ID: 36658531
[TBL] [Abstract][Full Text] [Related]
13. Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease.
Santoro A; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Degli Esposti L
J Nephrol; 2022 Mar; 35(2):463-472. PubMed ID: 34115311
[TBL] [Abstract][Full Text] [Related]
14. Management of Chronic Hyperkalemia in Patients With Chronic Kidney Disease: An Old Problem With News Options.
Morales E; Cravedi P; Manrique J
Front Med (Lausanne); 2021; 8():653634. PubMed ID: 34150795
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor.
Johnson M; Morrison FJ; McMahon G; Su M; Turchin A
Am Heart J; 2023 Apr; 258():49-59. PubMed ID: 36642227
[TBL] [Abstract][Full Text] [Related]
16. Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care.
Pecoits-Filho R; Fliser D; Tu C; Zee J; Bieber B; Wong MMY; Port F; Combe C; Lopes AA; Reichel H; Narita I; Stengel B; Robinson BM; Massy Z;
J Clin Hypertens (Greenwich); 2019 Jul; 21(7):991-1001. PubMed ID: 31169352
[TBL] [Abstract][Full Text] [Related]
17. Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena.
Epstein M
Kidney Int Suppl (2011); 2016 Apr; 6(1):20-28. PubMed ID: 30675416
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
Polson M; Lord TC; Kangethe A; Speicher L; Farnum C; Brenner M; Oestreicher N; Alvarez P
J Manag Care Spec Pharm; 2017 Apr; 23(4-a Suppl):S2-S9. PubMed ID: 28436256
[TBL] [Abstract][Full Text] [Related]
19. Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review.
Fonseca C; Brito D; Branco P; Frazão JM; Silva-Cardoso J; Bettencourt P
Rev Port Cardiol (Engl Ed); 2020 Sep; 39(9):517-541. PubMed ID: 32868174
[TBL] [Abstract][Full Text] [Related]
20. Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence.
Hundemer GL; Talarico R; Tangri N; Leon SJ; Bota SE; Rhodes E; Knoll GA; Sood MM
Clin J Am Soc Nephrol; 2021 Mar; 16(3):365-373. PubMed ID: 33608262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
